Polymorphism | RA Case, n (%) | Rotterdam study Control, n (%) | Unadjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
---|---|---|---|---|---|---|
ER22/23EK | ||||||
Non-carriers | 336 (91.3%) | 4721 (93.8%) | reference | reference | ||
Carriers | 32 (8.7%)1 | 312 (6.2%)2 | 1.44 (0.99-2.10) | 0.058 | 1.42 (0.95-2.13) | 0.086 |
N363S | ||||||
Non-carriers | 352 (95.7%) | 4664 (92.7%) | reference | reference | ||
Carriers | 16 (4.3%) | 369 (7.4%)3 | 0.58 (0.35-0.95) | 0.032 | 0.55 (0.32-0.96) | 0.034 |
BclI | ||||||
Non-carriers | 176 (47.8%) | 1979 (39.3%) | reference | reference | ||
Carriers* | 192 (52.2%) | 3054 (60.7%) | 0.71 (0.57-0.87) | 0.001 | 0.73 (0.58-0.91) | 0.006 |
Heterozygous carriers | 149 (40.5%) | 2370 (47.1%) | 0.71 (0.56-0.89) | 0.003 | 0.72 (0.57-0.92) | 0.008 |
Homozygous carriers | 43 (11.7%) | 684 (13.6%) | 0.71 (0.50-0.996) | 0.047 | 0.74 (0.52-1.07) | 0.108 |
9β | ||||||
Non-carriers | 233 (63.3%) | 3445 (68.4%) | reference | reference | ||
Carriers* | 135 (36.7%) | 1588 (31.6%) | 1.26 (1.01-1.57) | 0.041 | 1.26 (1.00-1.60) | 0.050 |
Heterozygous carriers | 124 (33.7%) | 1437 (28.6%) | 1.28 (1.02-1.60) | 0.035 | 1.13 (1.004-1.62) | 0.047 |
Homozygous carriers | 11 (3.0%) | 151 (3.0%) | 1.08 (0.58-2.00) | 0.816 | 1.08 (0.58-2.22) | 0.720 |